INTRODUCTION
============

Electroconvulsive therapy (ECT) is a procedure which generalized seizures are induced by transcutaneous electrical stimuli to the brain. The ECT has been used in psychiatry since the early 1930s as an effective treatment of psychiatric disorders \[[@b1-cpn-17-523]\]. In the 1950s, ECT was receded with the development of antipsychotics and antidepressants. However, in the 1980s, when psychotropic drugs were found to be ineffective in some patients, ECT begun to gain importance again \[[@b2-cpn-17-523]\]. ECT is a preferred treatment modality in patients with major depression, affective disorders, schizophrenia, and other psychotic disorders, where pharmacological treatment is not adequate, and a rapid clinical response is desired. Several theories were hypothesized about mechanisms of action of ECT-including changes in cerebral blood flow and blood brain barrier, epigenetic modifications, changes in the levels of various hormones, neurotransmitters, and neurotrophic factors, alterations in neuroplasticity, and immune mechanisms \[[@b2-cpn-17-523],[@b3-cpn-17-523]\]. In order for ECT to be effective, the required seizure time is \> 25 seconds \[[@b4-cpn-17-523],[@b5-cpn-17-523]\].

Anesthesia is an important factor for the safety and efficacy of ECT \[[@b6-cpn-17-523],[@b7-cpn-17-523]\]. The anesthetic agents should provide rapid induction and recovery, must have fewer side effects, and should not reduce the duration and quality of ECT \[[@b8-cpn-17-523]\]. Thiopental shortens duration of the seizures, extends recovery, and causes hypotension. Etomidate has minimal hemodynamic and cardiac adverse effects; on the other hand, it prolongs seizure duration and recovery time. Propofol is the most frequently used hypnotic agent in ECT. It is also known that propofol reduces duration of seizures, however its effect on seizure threshold is controversial. Wang *et al*. \[[@b9-cpn-17-523]\] emphasized that propofol can induce epileptiform electroencephalogram (EEG) changes after administration of low (\< 1 mg/kg) doses, and this epileptiform EEG pattern was attenuated after administration of higher propofol doses.

In this study, 2 different dose regimens of propofol (low dose: \< 1 mg/kg, high dose: ≥ 1 mg/kg) were compared by assessing the effects on duration of the seizures, required energy for the seizures, and seizure threshold over the course of ECT.

METHODS
=======

After approval of the local ethical committee (Decree \#14/13, January 4, 2019), the electronic medical records of the patients who received ECT sessions with a standardized protocol of anesthetic drugs (propofol and succinylcholine) between January 2015 and September 2018 were analyzed retrospectively. Patients with missing data, who received drugs that can affect seizures, and who received a different protocol of anesthetic drugs were excluded from the study.

It was observed that there was a significant difference in the regimen of propofol doses due to the different application methods of anesthesia of multiple anesthesiologists. Because of this reason, it was decided to evaluate the patients in 2 groups according to propofol doses. Group LP (n = 91): patients who received low dose propofol (\< 1 mg/kg). Group HP (n = 74): patients who received high dose propofol (≥ 1 mg/kg). Propofol doses were calculated by dividing the total amount of propofol administered by the weight of the patient.

Data collection included demographic characteristics, psychiatric diagnosis, overall number of ECT sessions performed, doses and types of anesthetic drugs used, seizure thresholds, seizure durations, complications during the ECT sessions, clinical severity scores on admission and clinical improvement scores following ECT therapy. Before ECT, all patients had preanesthetic evaluation and informed consent was obtained from all patients. Pre-procedural medications of patients were reordered by a psychiatrist. Patients were scheduled for consecutive ECT sessions three times a week (Monday, Wednesday, Friday; except weekends).

In the periprocedural period, patients received no drugs which can affect seizures such as anticonvulsant, benzodiazepine, theophylline or methylphenidate. No premedication was administered to patients. Routine monitorization of non-invasive blood pressure, heart rate, and peripheral oxygen saturation were established. Seizures were monitored with a two-channel EEG. Following pre-oxygenation with 100% oxygen via face mask, propofol administered intravenously until the patient was unconsciousness, and loss of eyelash reflex. Succinylcholine was then administered for muscle relaxation, and ventilation was assisted. The drug doses for induction of anesthesia in the subsequent sessions were determined based on the previous administered drug doses. Electrical stimulus was delivered via bifrontotemporal electrodes the stimulus with the dosage titration procedure. Seizure threshold was defined as the stimulus dosage that elicited a seizure activity on EEG of at least 25 seconds duration. Duration of the seizure activity on EEG was evaluated by the psychiatrist. No additional anesthetic or muscle relaxant medications were given after the initial bolus. After the procedure, patients were monitored at the recovery room until modified Aldrete scores were 9 or higher.

The scores of the clinical severity of illness on admission and clinical improvement scores following ECT were assessed with Clinical Global Impressions scale (CGI) according to the clinician's judgement, and these data were acquired from the clinical charts. The severity of the illness was rated on the 7-point CGI-Severity (CGI-S) scale from 1 (normal, not at all ill) to 7 (among the most extremely ill patients) \[[@b10-cpn-17-523]\]. The clinical improvement following ECT therapy was rated on the 7-point CGI-mprovement (CGI-I) scale from 1 (very much improved since the initiation of treatment) to 7 (very much worse since the initiation of treatment) \[[@b10-cpn-17-523]\]. For evaluation of the response to ECT therapy, we dichotomized patients as responders (CGI-I score of 1, 2, and 3), and non-responders (CGI-I score of 4, 6, and 7).

Statistics
----------

Statistical analyses were performed using computerized statistical software: IBM SPSS, version 24.0 (IBM Corp., Armonk, NY, USA). For intergroup comparisons of categorical data, Pearson's chi-square test was applied. For continuous variables, the Kolmogorov--Smirnov test was used for the normality of data distribution and followed by the Mann--Whitney *U* test when a significant difference was found (*p* \< 0.05). The correlation of the variables (the required energy for seizures and the duration of seizures) were analyzed using Pearson correlation analysis. Friedman variance analysis was used to evaluate the repeated measures of the required energy for seizures in the consecutive ECT sessions, and *post-hoc* Wilcoxon signed-ranks test was used for paired comparison of these repeated measures. All data were presented as median (min--max) or numbers as appropriate. A *p* \< 0.05 was considered to be statistically significant.

RESULTS
=======

A total of 971 ECT sessions were performed on 165 patients, including 74 males (55%) and 91 female (45%) patients. Three of the female patients underwent ECT because of pregnancy. It was observed that a mean of 1.56 mg/kg (median 1.83 mg/kg \[min 1--max 2.56\]) propofol was administered to the patients in high dose propofol group, and a mean of 0.67 mg/kg (median 0.6 mg/kg \[min 0.4--max 0.89\]) propofol was administered to the patients in low dose propofol group. There were no statistically significant differences between the groups in the demographic and clinical characteristics of the patients ([Table 1](#t1-cpn-17-523){ref-type="table"}).

There was a statistically significant difference in the required energy for seizures between the two groups. Required energy for seizures in Group HP were significantly higher than the Group LP in the 3rd, 4th, 5th, 6th, 7th, 8th, and 9th sessions (*p* \< 0.05) ([Table 2](#t2-cpn-17-523){ref-type="table"}). There was a statistically significant difference in the duration of seizures between the two groups. The duration of seizures in the Group HP were significantly lower than the Group LP in the 1st, 2nd, 4th, 5th, 7th, and 8th sessions (*p* \< 0.05) ([Table 2](#t2-cpn-17-523){ref-type="table"}). The correlation between the duration of seizures and the required energy for seizures showed a negative and statistically significant difference (*p* \< 0.05). It was found that shorter duration of seizures correlated higher energy, in the 2nd, 3rd, 4th, 6th, 7th, 8th, and 9th sessions in Group HP, and the 2nd, 3rd, 4th, and 5th sessions in Group LP ([Table 3](#t3-cpn-17-523){ref-type="table"}). This means that higher electricity stimulus was needed to acquire a minimum length of seizure (\> 25 sn) during the course of ECT in higher propofol doses.

The measurement of the required energy for seizures in the first 6 sessions in Group HP showed a statistically significant difference (*p* \< 0.005). All binary pairings were found to be statistically significant with *post-hoc* Wilcoxon signed ranks analysis (*p* \< 0.005). The measurement of the required energy for seizures in the first 6 sessions in Group LP also showed a statistically significant difference (*p* \< 0.005). All binary pairings--except the 1st session and 9th session pair--were found to be statistically significant with *post-hoc* Wilcoxon signed ranks analysis (*p* \< 0.005). There was no statistically significant difference between the low-dose and high-dose propofol groups in duration of seizures with *post-hoc* Wilcoxon signed ranks analysis and Friedman variance analysis (*p* \> 0.005) ([Table 4](#t4-cpn-17-523){ref-type="table"}).

The correlation of the required energy for seizures and the duration of seizures over the course of the ECT sessions is presented in [Figure 1](#f1-cpn-17-523){ref-type="fig"}. Although there was an increase in the seizure threshold over the course of ECT in both groups, this increase was found to be much more pronounced in the high-dose propofol group according to the low-dose propofol group. Longer duration of seizures was observed in the low-dose propofol group ([Fig. 1](#f1-cpn-17-523){ref-type="fig"}).

The clinical response to the treatment according to the propofol doses was assessed with CGI-I scale. The number of responders (the number of patients with CGI-I scores 1, 2, and 3) was 65 in Group-HP, and 84 in Group-LP. This difference was not statistically significant (χ^2^ = 0.93, p = 0.33; *p* \< 0.05) ([Table 1](#t1-cpn-17-523){ref-type="table"}). A brief asystole was observed for once and sinus rhythm was obtained by intervention with atropine. Desaturation (n = 9), arrhythmia (n = 7), bradycardia (n = 5), hypertension (n = 1), self-limited rash (n = 3), and prolonged seizures (n = 3) were the observed complications of ECT. Cognitive dysfunction in 1 patient, amnesia in 2 patients, and prolonged confusion in 2 patients were observed as for the adverse effects of the therapy.

DISCUSSION
==========

The main finding of this study was, although an increase in the seizure threshold was observed in all patients over the course of ECT, this increment was much more pronounced in the high-dose propofol group in comparison with the low-dose propofol group.

In many clinical trials, possible determinants for initial seizure thresholds \[[@b11-cpn-17-523]\], changes in the seizure thresholds, and the duration of seizures in ECT have been researched widely \[[@b12-cpn-17-523]\]. It is well-established that changes in the seizure threshold occur during the course of ECT \[[@b12-cpn-17-523],[@b13-cpn-17-523]\]. Sex, age, electrode placement, and the cumulative number of treatments are associated with an increase in seizure threshold which is attributed to anticonvulsant effect of ECT \[[@b14-cpn-17-523]\]. Although, anesthetic drugs are known to have effect on seizure thresholds, the role of propofol on the seizure threshold during the course of ECT is uncertain.

Propofol is a frequently used anesthetic agent for both sedation and hypnosis. Propofol can inhibit seizure activity, but it can also have a proconvulsant impact. It was specified in a study that, propofol can act as a pro or anticonvulsant agent in a dose-depended fashion \[[@b9-cpn-17-523]\]. Regarding to that study, a low dose of propofol (0.5 to 1 mg/kg) was associated with epileptiform patterns on EEG, on the contrary a large dose of propofol (2 to 2.5 mg/kg) attenuated the amplitudes of all EEG waves \[[@b9-cpn-17-523]\]. This result was also concluded in animal studies \[[@b15-cpn-17-523],[@b16-cpn-17-523]\].

Several studies have compared the effects of propofol and different hypnotic agents in ECT. Propofol was shown to shorten the duration of seizures, however, it was thought that it had no effect on seizure threshold during the ECT treatment \[[@b17-cpn-17-523],[@b18-cpn-17-523]\]. On the contrary, it was found in a study comparing the effects of etomidate and propofol that, the patients who had received propofol necessitated significantly higher amounts of electrical stimulus over the course of ECT \[[@b19-cpn-17-523]\]. Similar to all of these findings, in this study patients who were administered larger doses of propofol (1 to 2.56 mg/kg) required significantly increasing doses of electrical stimuli for seizures on the course of ECT therapy. Higher doses of propofol were associated with significantly shorter seizures.

Mechanism of action of propofol is to increase the inhibitory tonus in the cranial nervous system, by increasing gamma-aminobutyric acid (GABA) which is the principal inhibitory neurotransmitter. It has also been shown that electroconvulsive shock results in increased GABA concentrations in several neural regions \[[@b20-cpn-17-523],[@b21-cpn-17-523]\]. Anticonvulsant effect of ECT was attributed to enhancement of GABAergic or endogenous opiate neurotransmission, which in turn could lead to a progressive rise in seizure threshold \[[@b13-cpn-17-523]\]. The significant increase in the seizure threshold over the course of ECT in high-dose propofol group may be the result of the additive effect of both higher doses of propofol and the anticonvulsant effect of ECT on GABA concentrations. At this point, randomized controlled trials are needed to explain the relation between propofol doses and seizure thresholds.

Some of the previous authors have suggested that rise in the seizure threshold was directly related with the clinical efficacy \[[@b22-cpn-17-523]\]. In contrast to these findings, following studies have failed to support this hypothesis \[[@b20-cpn-17-523],[@b23-cpn-17-523]\]. Accordingly, clinical outcomes of this study were not affected by the magnitude of the rise in the seizure threshold.

ECT is related to some complications such as bone and soft tissue injury, sustained seizure activity, significant changes in autonomic function, facial flush, respiratory distress and oxygen desaturation \[[@b24-cpn-17-523],[@b25-cpn-17-523]\]. Bradycardia, hypotension, and cardiac pause or a brief asystole can be caused by parasympathetic response \[[@b26-cpn-17-523]\]. Tachycardia and hypertension are related to sympathetic activation \[[@b27-cpn-17-523]\]. Postprocedural headache and myalgia (due to muscle fasciculations with succinylcholine) can be reduced with rocuronium and sugammadex \[[@b28-cpn-17-523]\]. The prevalence of the complications that we observed in this study was consistent with the literature.

1.  The strengths of this study are, despite the lack of randomization, the two groups were well matched in terms of demographic and clinical characteristics. The standard type of anesthetic agents that were used for ECT allowed us to compare the different induction regimens of individual anesthesiologists. In many studies, anesthetic agents were tended to be switched in a single course of ECT, however, in this study the anesthetic drug doses in the subsequent sessions were determined based on the previous administered drug doses. Additionally, the large number of patients in comparison with other studies is another strength of this study.

First limitation of this study is that it is a retrospective analysis and it cannot be generalized yet. In the daily clinical practice of anesthesia, like many anesthetics, propofol is administered by titration until a desired clinical effect is achieved \[[@b29-cpn-17-523]\]. Although, a propofol dose between 1 to 2 mg/kg is adequate for induction of anesthesia in most cases, propofol requirement can be influenced by several factors which can affect pharmacodynamics and pharmacokinetics, such as degree of anxiety, speed of injection, cardiac output, lean body mass, drug interactions, etc. \[[@b30-cpn-17-523],[@b31-cpn-17-523]\]. Because of the retrospective nature of the study, we could not be able to standardize these variables, nor study the effects of a fixed dose of propofol. Thus, we observed different propofol dosing regimens individualized for patients.

In conclusion, although an increase in the seizure threshold can be observed in all patients over the course of ECT, higher propofol doses (≥ 1 mg/kg) in induction of anesthesia can lead to a more progressive rise in seizure threshold over the course of ECT. Larger propofol doses according to lower doses are associated with shorter duration of seizures. Thus, when propofol doses remained below 1 mg/kg, it may be beneficial for inducing longer duration of seizures without a significant contribution to the rise of seizure threshold.
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###### 

Demographic and clinical characteristics of the patients

  Variable                         Group HP (n = 74)   Group LP (n = 91)   z        χ^2^    *p* value
  -------------------------------- ------------------- ------------------- -------- ------- ----------------------------------------------------
  General characteristics                                                                   
   Age (yr)                        36.7 ± 7.9          36.9 ± 7.4          −0.174           0.862
   Weight (kg)                     69.4 ± 9.7          72.4 ± 9.7          −0.305           0.721
   Succinylcholine (mg/kg)         0.6 ± 0.1           0.5 ± 0.1           −2.737           0.091
   Propofol (mg/kg)                1.5 ± 0.4           0.7 ± 0.1           −3.615           \<0.001[\*](#tfn4-cpn-17-523){ref-type="table-fn"}
   Session                         6 (1--13)           6 (1--12)           −1.672           0.095
  Gender                                                                                    
   Female                          46 (62.2)           45 (49.5)                    2.666   0.103
   Male                            28 (37.8)           46 (50.5)                            
  Severity of the illness                                                                   
   CGI-S (5/6/7)                   22/40/12            26/44/21                     1.240   0.538
  Clinical response to treatment                                                            
   Responders                      65 (87.8)           84 (92.3)                    0.931   0.335
  Diagnoses                                                                                 
   Major depressive disorder       24 (32.4)           17 (18.7)                    6.952   0.138
   Bipolar disorder                14 (18.9)           14 (15.4)                            
   Psychotic disorders             17 (23.0)           36 (39.6)                            
   Schizoaffective disorder        5 (6.8)             7 (7.7)                              
   Schizophrenia                   14 (18.9)           17 (18.7)                            

Values are presented as mean±standard deviation, median (min--max), or number (%).

CGI-S, Clinical Global Impressions-Severity scale.

Mann--Whitney *U* analysis, Pearson's chi-square;

*p* \< 0.05.

###### 

Intergroup distribution of the required energy for seizures and the duration of seizures over the course of the electroconvulsive therapy sessions

  Session   Required energy for seizures   Duration of seizures                                                                                                                                                
  --------- ------------------------------ ---------------------- ---- ------------------- ---------- ----------------------------------------------------- ---- --------------- ---- --------------- -------- -------
  1         74                             26.65 (10.7--71)       91   27 (20--53)         −0.069     0.945                                                 74   24 (0--90)      91   34 (10--90)     −3.240   0.001
  2         71                             32.5 (11.4--88)        90   31.45 (13.5--57)    −1.778     0.075                                                 71   25 (0--72)      90   30 (10--77)     −2.746   0.006
  3         67                             35 (17.1--93)          86   31.7 (13.5--59)     −2.516     0.012[\*](#tfn6-cpn-17-523){ref-type="table-fn"}      67   28 (10--78)     86   30.5 (10--70)   −1.295   0.195
  4         63                             40.6 (21--95.1)        79   31.7 (15--60.8)     −3.879     \< 0.001[\*](#tfn6-cpn-17-523){ref-type="table-fn"}   63   25 (0--56)      79   30 (0--56)      −2.225   0.026
  5         57                             45.1 (21--93.7)        66   34.7 (22.3--60.8)   −3.907     \< 0.001[\*](#tfn6-cpn-17-523){ref-type="table-fn"}   57   26 (10--95)     66   32.5 (10--60)   −2.639   0.008
  6         46                             50 (21--100.2)         50   35.5 (22.5--69.3)   −4.241     \< 0.001[\*](#tfn6-cpn-17-523){ref-type="table-fn"}   46   25 (10--60)     50   30 (0--55)      −1.627   0.104
  7         34                             51.95 (25.3--112.6)    28   35.5 (20.7--71.3)   −3.787     \< 0.001[\*](#tfn6-cpn-17-523){ref-type="table-fn"}   34   26.5 (10--50)   28   33.5 (16--52)   −2.239   0.025
  8         25                             57.8 (29.7--126.7)     15   35.5 (20.7--69.9)   −3.396     0.001[\*](#tfn6-cpn-17-523){ref-type="table-fn"}      25   25 (0--55)      15   32 (20--50)     −2.044   0.041
  9         11                             61 (29.7--136.9)       6    34.7 (20.7--36.9)   −2.312     0.021[\*](#tfn6-cpn-17-523){ref-type="table-fn"}      11   25 (0--50)      6    36 (30--43)     −1.461   0.144
  10        4                              49.05 (30.4--152)      1    31.7 (31.7--31.7)   \< 0.001   1.000                                                 4    37.5 (12--40)   1    30 (30--30)     −0.725   0.468
  11        2                              49.55 (31--68.1)       1    31 (31--31)         −0.707     0.480                                                 2    35 (35--35)     1    45 (45--45)     −1.414   0.157
  12        2                              53.85 (31--76.7)       1    34.1 (34.1--34.1)   \< 0.001   1.000                                                 2    30 (30--30)     1    40 (40--40)     −1.414   0.157

Mann--Whitney *U* analysis;

*p* \< 0.05.

###### 

Correlation of the required energy for seizures and the duration of seizures

  Session   Group HP   Group LP                                                                       
  --------- ---------- ---------- ----------------------------------------------------- ---- -------- -----------------------------------------------------
  1         74         −0.227     0.052                                                 91   −0.165   0.118
  2         71         −0.319     0.007[\*](#tfn8-cpn-17-523){ref-type="table-fn"}      90   −0.264   0.012[\*](#tfn8-cpn-17-523){ref-type="table-fn"}
  3         67         −0.370     0.002[\*](#tfn8-cpn-17-523){ref-type="table-fn"}      86   −0.314   0.003[\*](#tfn8-cpn-17-523){ref-type="table-fn"}
  4         63         −0.378     0.002[\*](#tfn8-cpn-17-523){ref-type="table-fn"}      79   −0.370   0.001[\*](#tfn8-cpn-17-523){ref-type="table-fn"}
  5         57         −0.218     0.104                                                 66   −0.447   \< 0.001[\*](#tfn8-cpn-17-523){ref-type="table-fn"}
  6         46         −0.552     \< 0.001[\*](#tfn8-cpn-17-523){ref-type="table-fn"}   50   −0.173   0.230
  7         34         −0.445     0.008[\*](#tfn8-cpn-17-523){ref-type="table-fn"}      28   −0.147   0.455
  8         25         −0.557     0.004[\*](#tfn8-cpn-17-523){ref-type="table-fn"}      15   −0.215   0.441
  9         11         −0.631     0.037[\*](#tfn8-cpn-17-523){ref-type="table-fn"}      6    −0.022   0.966
  10        4          0.912      0.088                                                 1             
  11        2                                                                           1             
  12        2                                                                           1             

Pearson correlation;

*p* \< 0.05.

###### 

The variance of the required energy for seizures in the first 6 sessions

  Session                        Group HP   Group LP                                                                          
  ------------------------------ ---------- ---------- --------------------------------------------------- --------- -------- ---------------------------------------------------
  Required energy for seizures                                                                                                
   Friedman test                 167.983               0.000[\*](#tfn10-cpn-17-523){ref-type="table-fn"}   114.097            0.000[\*](#tfn10-cpn-17-523){ref-type="table-fn"}
   Wilcoxon signed ranks                                                                                                      
    Session 2--1                            −5.963     0.000[\*](#tfn10-cpn-17-523){ref-type="table-fn"}             −4.738   0.000[\*](#tfn10-cpn-17-523){ref-type="table-fn"}
    Session 3--1                            −6.603     0.000[\*](#tfn10-cpn-17-523){ref-type="table-fn"}             −5.535   0.000[\*](#tfn10-cpn-17-523){ref-type="table-fn"}
    Session 4--1                            −6.580     0.000[\*](#tfn10-cpn-17-523){ref-type="table-fn"}             −6.066   0.000[\*](#tfn10-cpn-17-523){ref-type="table-fn"}
    Session 5--1                            −6.368     0.000[\*](#tfn10-cpn-17-523){ref-type="table-fn"}             −6.102   0.000[\*](#tfn10-cpn-17-523){ref-type="table-fn"}
    Session 6--1                            −5.742     0.000[\*](#tfn10-cpn-17-523){ref-type="table-fn"}             −5.069   0.000[\*](#tfn10-cpn-17-523){ref-type="table-fn"}
    Session 7--1                            −5.012     0.000[\*](#tfn10-cpn-17-523){ref-type="table-fn"}             −4.106   0.000[\*](#tfn10-cpn-17-523){ref-type="table-fn"}
    Session 8--1                            −4.286     0.000[\*](#tfn10-cpn-17-523){ref-type="table-fn"}             −3.111   0.002[\*](#tfn10-cpn-17-523){ref-type="table-fn"}
    Session 9--1                            −2.803     0.005[\*](#tfn10-cpn-17-523){ref-type="table-fn"}             −1.753   0.080
    Session 3--2                            −5.715     0.000[\*](#tfn10-cpn-17-523){ref-type="table-fn"}             −4.667   0.000[\*](#tfn10-cpn-17-523){ref-type="table-fn"}
    Session 4--2                            −6.190     0.000[\*](#tfn10-cpn-17-523){ref-type="table-fn"}             −5.032   0.000[\*](#tfn10-cpn-17-523){ref-type="table-fn"}
    Session 5--2                            −6.175     0.000[\*](#tfn10-cpn-17-523){ref-type="table-fn"}             −5.252   0.000[\*](#tfn10-cpn-17-523){ref-type="table-fn"}
    Session 6--2                            −5.590     0.000[\*](#tfn10-cpn-17-523){ref-type="table-fn"}             −4.462   0.000[\*](#tfn10-cpn-17-523){ref-type="table-fn"}
    Session 4--3                            −5.774     0.000[\*](#tfn10-cpn-17-523){ref-type="table-fn"}             −4.178   0.000[\*](#tfn10-cpn-17-523){ref-type="table-fn"}
    Session 5--3                            −6.058     0.000[\*](#tfn10-cpn-17-523){ref-type="table-fn"}             −4.678   0.000[\*](#tfn10-cpn-17-523){ref-type="table-fn"}
    Session 6--3                            −5.615     0.000[\*](#tfn10-cpn-17-523){ref-type="table-fn"}             −4.146   0.000[\*](#tfn10-cpn-17-523){ref-type="table-fn"}
    Session 5--4                            −5.862     0.000[\*](#tfn10-cpn-17-523){ref-type="table-fn"}             −4.119   0.000[\*](#tfn10-cpn-17-523){ref-type="table-fn"}
    Session 6--4                            −5.373     0.000[\*](#tfn10-cpn-17-523){ref-type="table-fn"}             −3.449   0.001[\*](#tfn10-cpn-17-523){ref-type="table-fn"}
    Session 6--5                            −3.960     0.000[\*](#tfn10-cpn-17-523){ref-type="table-fn"}             −2.555   0.011[\*](#tfn10-cpn-17-523){ref-type="table-fn"}
  Duration of seizures                                                                                                        
   Friedman test                 1.416                 0.923                                               6.179              0.289

Friedman variance analysis and *post-hoc* Wilcoxon signed ranks analysis;

*p* \< 0.05.
